The European Association for the Study of the Liver (EASL) aims to contribute to answering this question by stressing the necessity of extending screening programmes to liver cancer, notably for a well-defined population of people at risk of developing liver cancer.
The Best of ILC 2019 slide decks on Liver Tumours provides highlights of new data presented at the International Liver Congress™ 2019. The slide decks are supported by an unrestricted education grant from Bayer, Eisai and MSD. Bayer, Eisai and…
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepato-cellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The following Clinical Practice Guidelines will give up-to-date advice for the clinical management of patients with hepatocellular carcinoma, as well as providing an in-depth review of all the relevant data leading to the conclusions herein.
Benign liver tumours are a heterogeneous group of lesions with different cellular origins, as summarized by an international panel of experts sponsored by the World Congress of Gastroenterology in 1994. These lesions are frequently found incidentally as a consequence of the widespread use of imaging tests and often have a benign course. Some of these…
These guidelines result from a joint collaboration between the European Association for the Study of the Liver (EASL) and the European Organization for Research and Treatment of Cancer (EORTC). The EASL–EORTC Clinical Practice Guidelines provide common guidelines for the management of hepatocellular carcinoma (HCC) and define the use of surveillance, diagnosis, and therapeutic strategies recommended…
